Rubraca vs Lynparza

Listen to the article instead of reading through it.

0:00

Table of Contents

Overview

Rubraca

Lynparza

Comparative Analysis

Overview

Rubraca

Lynparza

Comparative Analysis

Introduction

For patients diagnosed with ovarian cancer resulting from BRCA mutations, certain drugs that inhibit the protein function associated with DNA repair can help manage disease progression and symptoms. Rubraca and Lynparza are two such medications prescribed for this type of advanced cancer. Both interact differently within the body but have been found to be effective in impeding tumor growth in patients with ovarian cancer. Rubraca, also known as Rucaparib, is a Poly (ADP-ribose) Polymerase inhibitor (PARPi). It works by blocking an enzyme used by cells to repair their DNA when it becomes damaged. On the other hand, Lynparza or Olaparib is also a PARPi but has demonstrated efficacy against various types of cancers including breast and pancreatic cancers besides ovarian cancer. It works similarly but has been noted for its broad-spectrum impact on different forms of malignancies.

Rubraca vs Lynparza Side By Side

Attribute	Rubraca	Lynparza
Brand Name	Rubraca	Lynparza
Contraindications	Should not be taken with strong CYP3A inducers without consulting a doctor	Should not be taken with strong CYP3A inducers without consulting a doctor
Cost	$17,500 for 60 tablets of 200 mg	$14,300 for 112 capsules of 50 mg
Generic Name	Rucaparib	Olaparib
Most Serious Side Effect	Severe abdominal pain which could indicate a ruptured stomach/intestinal lining	Signs suggestive for lung inflammation - new or worsening coughing, chest discomfort
Severe Drug Interactions	Strong CYP3A inducers	Strong CYP3A inducers
Typical Dose	300-600 mg twice daily	300 mg taken orally twice daily

What is Rubraca?

Rucaparib (the generic name for Rubraca) and Olaparib (the generic name for Lynparza) are both PARP inhibitors, a class of medication used in cancer treatment. These drugs have significantly transformed the landscape of ovarian cancer therapy. Rucaparib was first approved by the FDA in 2016 as a maintenance treatment for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. Rubraca works by preventing DNA repair in cancer cells, leading to their death and slowing down tumor growth.

Lynparza, on the other hand, has been approved since 2014 and also functions as a PARP inhibitor but is additionally indicated for breast cancers with BRCA gene mutations. While both medications work similarly - trapping PARPs on damaged DNA strands which leads to cell death -, they do display differences in side effect profiles and specific indications due to differences in their chemical structure. Hence it's crucial to consider these factors when choosing between them.

What conditions is Rubraca approved to treat?

Rubraca is approved for the treatment of different forms of cancer:

Recurrent ovarian, fallopian tube or primary peritoneal cancer
BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC)

On the other hand, Lynparza is FDA-approved to treat:

Ovarian and related cancers with certain genetic mutations (BRCA), as maintenance therapy after response to first-line platinum-based chemotherapy
Metastatic breast cancer in patients with a specific inherited genetic mutation (gBRCA)
Pancreatic adenocarcinoma with a specific inherited genetic mutation as maintenance therapy following at least 16 weeks of initial chemotherapy.

How does Rubraca help with these illnesses?

Rubraca aids in managing certain types of ovarian and prostate cancers by inhibiting the activity of a protein known as PARP. This protein is responsible for repairing damaged DNA within cells, which can include damage that leads to cancerous growth. By blocking this repair mechanism, Rubraca helps prevent these harmful cells from fixing their DNA and thereby continuing to multiply uncontrolled. In turn, this action promotes cell death and can slow or even halt tumor growth. Like serotonin in regard to depression management with Prozac, PARP plays an essential role in cellular reproduction—a process crucial to both normal function and disease progression like cancer. Thus, similar to how increasing serotonin levels can mitigate depressive symptoms, obstructing PARP activity through Rubraca use may limit the negative impacts of specific cancers and assist patients in managing their conditions.

What is Lynparza?

Lynparza, the brand name for olaparib, is a poly (ADP-ribose) polymerase inhibitor (PARPi), which works by stalling cancer cell growth. It achieves this by preventing the repair of DNA damage in these cells, causing them to die off and thus limiting tumor progression. Lynparza was approved by the FDA in 2014 as one of the first PARP inhibitors on the market. Unlike Rubraca, another drug in its class, Lynparza does not solely target BRCA1 or BRCA2 mutations but can be effective against other forms of genetic alterations too. Its broader range makes it potentially beneficial for patients with varying types of cancers beyond those typically associated with BRCA mutations such as breast and ovarian cancer. The side-effect profile is also different from that of other drugs in its category; while nausea and fatigue are common side effects seen across many PARPi's including Rubraca, anemia occurs more frequently with Lynparza treatment.

What conditions is Lynparza approved to treat?

Lynparza is a medication that has been approved by the FDA for treating:

Advanced ovarian cancer in patients who have three or more lines of chemotherapy and who have certain types of BRCA gene mutation (germline and/or somatic).
HER2-negative metastatic breast cancer in patients with a specific type of inherited (germline) BRCA gene mutation, previously treated with chemotherapy.

How does Lynparza help with these illnesses?

Poly (ADP-ribose) polymerase (PARP) is an enzyme that plays a significant role in DNA repair. By inhibiting this enzyme, cancer cells with existing DNA damage—especially those with BRCA mutations—are unable to repair themselves and therefore die. Lynparza performs this function by specifically targeting the PARP enzyme, thereby halting the growth of certain types of cancers. In comparison to Rubraca, which is also a PARP inhibitor, Lynparza has been approved for use in more types of cancers and situations due to its broader clinical trial data set. Moreover, it can be used as maintenance therapy following response to first-line platinum chemotherapy for advanced ovarian cancer regardless of BRCA status—a distinction not yet achieved by Rubraca at the time of writing.

How effective are both Rubraca and Lynparza?

Both Rubraca (Rucaparib) and Lynparza (Olaparib) are breakthroughs in the treatment of ovarian cancer, specifically used for maintenance therapy. They both belong to a class of drugs known as PARP inhibitors and have shown significant efficacy in delaying disease progression compared to placebo.

Rubraca was initially approved by the FDA in 2016 while Lynparza had been available since 2014. Both drugs interfere with DNA repair mechanisms, leading to cell death particularly among cancer cells deficient in BRCA1 or BRCA2 genes. A double-blind clinical trial conducted on both these drugs showed similar efficacy rates for managing symptoms of advanced ovarian cancer after initial platinum-based chemotherapy.

In a comparison study between Rubraca and Lynparza, no significant disparities were noted regarding their effectiveness in treating ovarian cancer. However, certain studies suggest that patients treated with Rubraca may experience fewer adverse gastrointestinal effects than those prescribed Lynparza.

Rubraca has demonstrated its ability to decrease tumor size effectively from an early stage of treatment, making it widely accepted amongst oncologists worldwide. Optimal dosage is usually determined based on patient weight with adjustments made depending upon individual tolerance levels and side-effects experienced.

On another hand, several reviews indicate that Lynparza appears more effective than placebo when administered as monotherapy for relapsed ovarian cancers expressing BRCA mutations post-chemotherapy. Despite this evidence supporting its efficacy as stand-alone maintenance therapy following first-line chemotherapy completion remains limited but promising nonetheless due to its unique mechanism of action.

Lynparza might be preferred over other treatments if there's a need to avoid common side effects associated typically with chemotherapy such as alopecia or severe nausea despite being generally considered only after first-line treatment options have been exhausted due to higher costs associated with novel therapies like PARP inhibitors.

abstract image of a researcher studying a bottle of drug.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is Rubraca typically prescribed?

Oral dosages of Rubraca range from 300-600 mg twice daily, with studies indicating that the amount required can depend on factors such as body size and specific disease state. Unlike Prozac, it is not recommended for children or adolescents. In adults, dosage may be adjusted based on individual tolerability and clinical effect but should not exceed a maximum of 600 mg taken twice daily. Comparatively, Lynparza has a standard oral dosage of 300 mg also taken twice daily and again, the dosage can be modified depending on each patient's response to treatment and side effects experienced. Like Rubraca, Lynparza is not typically used in pediatric patients.

At what dose is Lynparza typically prescribed?

Lynparza treatment typically begins with a dosage of 300 mg taken orally twice daily, amounting to a total daily dose of 600 mg. The tablets should be swallowed whole and not chewed, crushed or split prior to swallowing. Dosing is continuous, meaning Lynparza is taken every day until disease progression or the patient experiences unacceptable side effects. If adverse reactions occur like nausea and anemia, the dosage can be reduced to 250 mg twice daily (total daily dose of 500mg). The lowest step for dose reduction in case of further toxicity is 200mg twice daily (total daily dose of 400mg). It's important that any changes in dosing are overseen by a healthcare professional.

What are the most common side effects for Rubraca?

Common side effects of Rubraca can include:

Nausea and vomiting
Fatigue (general weakness and tiredness)
Abdominal pain
Decreased appetite
Diarrhea or constipation
Dyspnea (difficulty in breathing)
Anemia
Thrombocytopenia (low platelet count)
Neutropenia (low neutrophil count, a type of white blood cell that fights infection) -Rash or skin changes -Elevated liver function tests

On the other hand, Lynparza may cause these common side effects:

-Nausea and vomiting -Fatigue or asthenia -Anemia -Diarrhea -Joint pain/muscle ache
-Decreased appetite
-Cough

abstract image of a patient experiencing side effect

Are there any potential serious side effects for Rubraca?

While both Rubraca and Lynparza are effective in treating certain types of cancers, they can potentially cause serious side effects. These may include:

Severe nausea or vomiting that doesn't improve with anti-nausea medication
Signs of an allergic reaction including hives; difficulty breathing; swelling of your face, lips, tongue, or throat
Changes in vision such as light sensitivity, blurred vision, or loss of vision
Rapid heartbeat (tachycardia) or feeling like you might pass out
Low levels of red blood cells (anemia) causing extreme tiredness and lack of energy
Unusual bruising or bleeding which could be a sign of low platelet count
Symptoms related to kidney problems: changes in the amount or coloration of urine, lower back pain

Moreover, for Rubraca specifically: severe abdominal pain which could indicate a ruptured stomach/intestinal lining. for Lynparza specifically: signs suggestive for lung inflammation - new or worsening coughing, chest discomfort

If you experience any serious symptoms while on these medications it is crucial to seek immediate medical attention.

What are the most common side effects for Lynparza?

Lynparza, like Rubraca, is used for the treatment of certain types of cancer. It can cause a range of symptoms including:

Nausea or vomiting
Diarrhea
Loss of appetite leading to weight loss
Headache and dizziness
Fatigue that leads to sleep problems
Common cold symptoms such as stuffy nose and sore throat
Unusual bruising or bleeding due to decreased blood cells counts -Anemia resulting in paleness and increased tiredness -Stomach pain potentially caused by inflammation of the stomach lining.

It's important to note that not everyone experiences these side effects and they may lessen over time as your body adjusts to the drug. However, if any persist or worsen you should contact your healthcare provider immediately.

Are there any potential serious side effects for Lynparza?

While Lynparza is generally well-tolerated, it can still cause serious side effects in certain situations. Signs of severe complications may include:

An allergic reaction: symptoms could be hives, difficulty breathing or swallowing, swelling of your lips, face, tongue or throat
Blood cell disorders: these might present as fatigue, unusual bruising or bleeding (including bloody stools), fever and susceptibility to infections
Lung problems: you might experience new or worsening coughing and shortness of breath
Kidney issues: urinating less than usual or not at all are potential signs
Severe nausea that prevents eating -Increased heart rate; fast pounding heartbeat

If any such symptoms occur while taking Lynparza seek immediate medical attention. It's important to have regular blood tests during treatment with this medication as it can lower blood cells count leading to frequent infections and slow healing process.

Contraindications for Rubraca and Lynparza?

Both Rubraca and Lynparza, as part of the class of drugs known as PARP inhibitors used to treat certain types of cancer, may worsen or cause new symptoms. If you notice any significant changes in your condition or experience severe side effects such as shortness of breath, chest pain, stomach pain, blood in urine or stools among others while taking these medications, please seek immediate medical attention.

Neither Rubraca nor Lynparza should be taken if you are using a strong CYP3A inducer (medicine that increases the activity of an enzyme called cytochrome P450 3A) without consulting your doctor first; these medications will require varying periods to clear from the system to prevent dangerous interactions with Rubraca and Lynparza. Always disclose all ongoing medication regimens to your physician before starting treatment with either drug.

How much do Rubraca and Lynparza cost?

For the brand name versions of these drugs:

The price of 60 tablets of Rubraca (200 mg) averages around $17,500, which works out to approximately $291/day.
The price for Lynparza is about $14,300 for a pack of 112 capsules (50 mg), working out to roughly $128/day.

Thus, if you are in the higher dosage range for Rubraca or Lynparza (600mg/day or more), then brand-name Lynparza could be less expensive on a per-day treatment basis. However, it's important to understand that cost should not be your primary consideration when choosing between these two medications.

Currently there are no generic versions available for either Rubraca (rucaparib) and Lynparza (olaparib). These prices can also vary greatly depending on your location and insurance coverage. Always consult with your healthcare provider and pharmacist before making any decisions regarding medication use and costs.

Popularity of Rubraca and Lynparza

Rucaparib, known by the brand name Rubraca, and olaparib, marketed as Lynparza, are both much-needed breakthroughs for cancer treatment. They are part of a class of drugs called PARP inhibitors which have shown promise in treating certain types of cancer such as ovarian and breast cancers.

In 2020, it was estimated that around 15,000 patients were treated with Rubraca in the US. This accounted for about 12% of all prescriptions written for PARP inhibitors. The use of this drug has been on an upward trend since its approval by the FDA in late 2016.

Olaparib (Lynparza), however, was prescribed to approximately 40 thousand people in the USA during the same year. In America alone, Olaparib accounts for nearly half (47%) of all PARP inhibitor prescriptions due to its broader range of approved indications compared to other drugs in this category. Since first being approved by health authorities back in December 2014 - two years ahead of Rucaparib - usage rates have remained relatively steady over time.

Conclusion

Both Rubraca (rucaparib) and Lynparza (olaparib) are used for treatment of patients with certain types of ovarian cancer, specifically those with BRCA mutation. These drugs have been shown in multiple clinical trials to be more effective than placebo treatments. Both medications function as PARP inhibitors, disrupting the ability of cancer cells to repair their own DNA, leading to cell death.

Rubraca is typically given after two or more chemotherapies, while Lynparza can be given earlier in treatment as a maintenance therapy following response to first-line platinum-based chemotherapy. The choice between these two depends on various factors including the patient's medical history and overall health status.

Both drugs are available only under prescription and may require an adjustment period during which side effects may become noticeable before therapeutic benefits are seen.

The side effect profiles for both Rubraca and Lynparza are similar; common adverse events include nausea, fatigue/weakness, vomiting among others. However, serious side effects such as myelodysplastic syndrome/Acute Myeloid Leukemia can occur with either drug although it is rare. It’s crucial that patients monitor their symptoms closely when starting treatment and contact their healthcare provider promptly if they notice any new or worsening symptoms.

Refrences

Annunziata, C. M., & Bates, S. E. (2010, February 11). PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer. F1000 Biology Reports. Faculty Opinions Ltd.http://doi.org/10.3410/b2-10
Syed, Y. Y. (2017, March 1). Rucaparib: First Global Approval. Drugs. Springer Science and Business Media LLC.http://doi.org/10.1007/s40265-017-0716-2